Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Account Payables (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Change in Account Payables data on record, last reported at $1.0 million in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 116.06% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $4.3 million, up 220.14%, while the annual FY2024 figure was $927000.0, 126.56% up from the prior year.
  • Change in Account Payables reached $1.0 million in Q3 2025 per TNXP's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.7 million in Q2 2024 and bottomed at -$6.4 million in Q3 2024.
  • Average Change in Account Payables over 3 years is $106272.7, with a median of $581000.0 recorded in 2024.
  • The widest YoY moves for Change in Account Payables: up 425.22% in 2024, down 725.07% in 2024.
  • A 3-year view of Change in Account Payables shows it stood at -$3.9 million in 2023, then skyrocketed by 114.76% to $581000.0 in 2024, then skyrocketed by 75.73% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $1.0 million in Q3 2025, $3.1 million in Q2 2025, and -$353000.0 in Q1 2025.